Implementation is moving forward on President Joe Biden’s Inflation Reduction Act (IRA) policy that allows Medicare to negotiate lower prescription drug prices. 16 March 2023
The impact of US President Joe Biden's Inflation Reduction Act is beginning to be felt, as Danish diabetes giant Novo Nordisk (NOV: N) announced plans to slash 15 March 2023
The US Department of Health and Human Services (HHS), through the Centers for Medicare and Medicaid Services (CMS), has announced 27 prescription drugs for whic 15 March 2023
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has unleashed a broadside against decision-makers in Brussels. 15 March 2023
Two American firms have agreed terms for the joint commercialization of the novel attention deficit/hyperactivity disorder (ADHD) candidate CTx-1301 (dexmethylp 13 March 2023
The influential Institute for Clinical and Economic Review (ICER), a Boston, USA-based pricing watchdog, has released a report into the cost-effectiveness of Le 1 March 2023
The Association of the British Pharmaceutical Industry (ABPI) has attempted to show that there is a better way than the existing Voluntary Pricing and Access Sc 1 March 2023
The need to guarantee a new regulatory category for ‘value-added medicines’ has been proposed by the Asociación Española de Medicamentos Genéricos (AESEG), the 27 February 2023
A final evidence report from the Institute for Clinical and Economic Review (ICER) on the affordability of multiple sclerosis (MS) drugs in the USA has found th 22 February 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.